All patients have reached the highest planned doses of DA-1726, keeping the company’s obesity program on track for late-2026 data.
The first wave of blockbuster obesity drugs changed the conversation by helping people feel full sooner. They work remarkably well for many patients, but they’ve also created a new expectation: successful weight loss often comes with eating significantly less.
What if that isn’t the only path?
Researchers are increasingly asking whether the next generation of obesity medicines should do more than suppress appetite. Could they also encourage the body to burn more energy, almost like turning up a thermostat that’s been set too low for years? And if so, could patients lose weight without feeling like every meal has become an exercise in restraint?
These questions sit at the core of MetaVia’s experimental obesity therapy, DA-1726, which this week reached a new development milestone. The clinical-stage biotechnology company announced that every active participant in Part 3 of its Phase 1 study has completed dose escalation and is now receiving the highest planned doses of the drug [1].
Think of dose escalation as teaching the body to get used to a new routine rather than throwing it in at the deep end. Instead of starting patients on the highest dose immediately, researchers gradually increase treatment over several weeks. The goal is to improve comfort and reduce side effects while eventually reaching doses that may deliver stronger results.
In MetaVia’s study, participants followed one of two approaches. One group moved from 16 mg to 48 mg, while another climbed more gradually from 16 mg to 32 mg before reaching 64 mg. The company says every active participant successfully arrived at those target doses, keeping the trial on track to report topline results in the fourth quarter of 2026.
“The successful completion of dose titration across both Part 3 cohorts represents an important milestone for the DA-1726 development program,” stated Hyung Heon Kim, President and CEO of MetaVia. “Reaching our highest planned dose levels in all active patients reinforces the favorable tolerability profile of DA-1726. We believe our efficient titration strategy could represent a meaningful competitive advantage over currently marketed obesity therapies.”
The obesity field has become crowded with therapies that work by reducing appetite. They’ve transformed treatment, but they’ve also exposed a new challenge. Simply eating less doesn’t necessarily rebuild metabolic health.
DA-1726 belongs to a newer generation of medicines designed to tackle obesity from two directions. Alongside signaling the brain to reduce hunger, it also activates another pathway linked to how the body uses energy. A simple way to think about it is this: today’s leading obesity drugs mostly lower the amount of fuel going into the engine. DA-1726 is trying to do that while also asking the engine to burn fuel more efficiently.
Before reaching human studies, MetaVia reported animal data suggesting mice receiving DA-1726 achieved weight loss comparable to some leading obesity therapies despite consuming more food. While animal findings rarely translate directly into people, they hint at an intriguing possibility: future obesity medicines may rely less on strict calorie restriction and more on restoring a healthier energy balance. If that eventually proves true in clinical trials, the conversation around obesity treatment could begin to shift, from simply eating less to metabolically doing more.
The company is also drawing attention to something that often receives less public attention than pounds lost: where fat is stored. Earlier Phase 1 findings showed participants receiving the 48 mg dose achieved an average weight loss of 9.1% after eight weeks, alongside meaningful reductions in waist circumference and improvements in blood sugar measures.
Waist circumference isn’t just another number on a tape measure. It acts as a rough window into visceral fat – the fat wrapped around organs that’s strongly linked to cardiovascular disease, type 2 diabetes and fatty liver disease. For longevity researchers, that’s where the story becomes especially interesting.
MetaVia also reported early signs of potential liver benefit, an area attracting growing attention as metabolic dysfunction-associated steatohepatitis (MASH) becomes one of the world’s fastest-growing liver diseases. Those findings remain preliminary and will require confirmation in larger studies, but they suggest DA-1726 could eventually be evaluated for more than obesity alone.
Kim believes the earlier results continue to differentiate the program. He said that robust data from their previously reported Phase 1 MAD study continue to demonstrate the unique, differentiated potential of their dual GLP-1/glucagon mechanism. He highlighted key findings from the trial, pointing to a 9.1% mean weight loss achieved with the 48 mg dose after only eight weeks of treatment, alongside significant reductions in waist circumference, improved glycemic measures, and early signs of direct liver benefits.
“With all patients now on their target doses, we remain focused on completing treatment and reporting topline data in the fourth quarter of 2026,” Kim added.
The obesity market now revolves around finding the next metabolic medicine. Obesity is increasingly understood as one piece of a much larger puzzle that includes cardiovascular disease, diabetes, liver disease and, ultimately, biological aging itself. DA-1726 is still early in development, and plenty of promising therapies have stumbled between Phase 1 and later-stage trials.
